



Baillie Gifford International Alpha Fund

Fourth Quarter 2022

About Baillie Gifford

Philosophy	Long-term investment horizon A growth bias Bottom-up portfolio construction High active share
Partnership	100% owned by 51 partners with average 20 years' service Ownership aligns our interests with those of our clients Enables us to take a thoughtful, long-term view in all that we do Stability, quality and consistency

Portfolio Summary

The strategy employs a bottom up stock-picking approach based on the fundamental research produced by Baillie Gifford's investment teams. The members of the Portfolio Construction Group (PCG) use their experience to identify the best ideas generated by the investment floor which are relevant to the strategy. The result is a diversified portfolio of quality growth companies which we believe has the potential to outperform the benchmark over the long term.

Fund Facts

K Class Ticker	BGIKX
Institutional Class Ticker	BINSX
Launch Date	February 07, 2008
Size	\$2,110.3m
Benchmark	MSCI ACWI ex US Index
Stocks (guideline range)	70-110
Current Number of Stocks	76
Active Share	86%*
Annual Turnover	18%
Style	Growth

*Relative to MSCI ACWI ex US Index. Source: Baillie Gifford & Co, MSCI.

Launch date refers to the longest running share class of the fund. This is earlier than the K and Institutional share class launch date.

Active Share is a measure of the Fund's overlap with the benchmark. An active share of 100 indicates no overlap with the benchmark and an active share of zero indicates a portfolio that tracks the benchmark.

International Alpha Portfolio Construction Group

Name	Years' Experience
Donald Farquharson*	35
Andrew Stobart	32
Tom Walsh*	19
Jenny Davis*	14
Chris Davies	11
Steve Vaughan	11

*Partner

Investors should consider the investment objectives, risks, charges and expenses carefully before investing. This information and other information about the Fund can be found in the prospectus and summary prospectus. For a prospectus and summary prospectus, please visit our website at bailliegifford.com/usmutualfunds Please carefully read the Fund's prospectus and related documents before investing. Securities are offered through Baillie Gifford Funds Services LLC, an affiliate of Baillie Gifford Overseas Ltd and a member of FINRA.

Fund Performance as of December 31, 2022



Gross Expense Ratio	
Share Class – K	0.58%
Share Class – Institutional	0.68%

Net Expense Ratio	
Share Class – K	0.58%
Share Class – Institutional	0.68%

Benchmark: MSCI ACWI ex US Index

The performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For the most recent month-end performance please visit the Fund's website at bailliegifford.com/usmutualfunds.

The Baillie Gifford Fund's performance shown assumes reinvestment of dividend and capital gain distributions and is net of management fees and expenses. From time to time, certain fees and/or expenses have been voluntarily or contractually waived or reimbursed, which has resulted in higher returns. Without these waivers or reimbursements, the returns would have been lower. Voluntary waivers or reimbursements may be applied or discontinued at any time without notice. Only the Board of Trustees may modify or terminate contractual fee waivers or expense reimbursements. All fees are described in the Fund's prospectus.

Returns are based on the above noted share class from April 28, 2017. Prior to that date returns are calculated based on the oldest share class of the Fund adjusted to reflect the current share class fees where these fees are higher. *Not annualized.

Expense Ratios: All mutual funds have expense ratios which represent what shareholders pay for operating expenses and management fees. Expense ratios are expressed as an annualized percentage of a fund's average net assets paid out in expenses. Expense ratio information is as of the Fund's current prospectus, as revised and supplemented from time to time.

The MSCI ACWI ex US Index is a free float-adjusted market capitalization weighted index that is designed to measure equity market performance in the global developed and emerging markets, excluding the United States. This unmanaged index does not reflect fees and expenses and is not available for direct investment. The Fund is more concentrated than the MSCI ACWI ex US Index.

Source: Baillie Gifford & Co, Bank of New York Mellon, MSCI. Share Class launch date: April 28, 2017. NAV returns in US dollars.

Stock Level Attribution

Quarter to December 31, 2022

Top Five Contributors

Asset Name	Contribution (%)
Tencent Music Entertainment	0.48
AIA	0.42
Shiseido	0.28
Richemont	0.28
Ryanair	0.25

Bottom Five Contributors

Asset Name	Contribution (%)
MercadoLibre	-0.37
MonotaRO	-0.28
Ritchie Bros Auctioneers (USA)	-0.27
Scout24	-0.27
Coupang	-0.24

One Year to December 31, 2022

Top Five Contributors

Asset Name	Contribution (%)
AIA	0.66
Edenred	0.51
Shopify	0.48
Deutsche Boerse	0.47
Rio Tinto	0.47

Bottom Five Contributors

Asset Name	Contribution (%)
Kingspan Group	-1.04
MercadoLibre	-1.00
Nidec	-0.80
Aker Carbon Capture	-0.74
Spotify Technology	-0.72

Five Years to December 31, 2022

Top Five Contributors

Asset Name	Contribution (%)
MercadoLibre	3.78
TSMC	1.81
Constellation Software	1.32
Rio Tinto	1.08
Edenred	1.08

Bottom Five Contributors

Asset Name	Contribution (%)
ASOS	-1.00
Magnit	-0.86
Temenos	-0.83
Discovery	-0.82
SEA Ltd	-0.80

Source: StatPro, MSCI, Baillie Gifford International Alpha Fund relative to MSCI ACWI ex US Index.

The performance data quoted represents past performance and it should not be assumed that transactions made in the future will be profitable or will equal the performance of the securities mentioned. For the most recent month-end performance please visit our website at bailliegifford.com/usmutualfund. A full list of holdings is available on request. The composition of the Fund's holdings is subject to change.

Attribution is shown relative to the benchmark therefore not all stocks shown are held in the portfolio. See the List of Holdings section of this report for the stocks held.

Market environment

The fourth quarter of the year saw a brief period of relief for financial markets as there are some signs that inflation has tempered, and supply chain bottlenecks are beginning to ease providing a welcome boost to sentiment. In particular it is worthy of note that manufacturing activity in Europe is showing signs of improvement and gas prices are beginning to fall from elevated levels. The decision from the Chinese communist party to relax Covid-19 restrictions towards the end of the period was also received well by markets and we hope will underpin a more supportive demand backdrop for a number of holdings. China's "zero-Covid" policy has weighed heavily on global demand and supply chains alike, and although there has since been an inevitable spike in cases, there is some tentative evidence now emerging that infection levels are peaking in major Chinese cities.

Performance

Against this backdrop the Fund marginally outperformed its benchmark over the period. Among the top contributors to performance were Chinese names, most notably those which benefit from China's re-opening.

Chinese entertainment streaming platform, Tencent Music Entertainment, has performed well over the period. The business has reported strong results during the past two quarters and management has noted an expansion in gross margins due to improved cost control, greater efficiencies and better control of content. Furthermore, despite revenues falling, the business has increased the number of paying users significantly.

Meanwhile, AIA Group, the leading Asian insurance company, also featured as a top contributor. The business stands to benefit from China's reopening, with many predicting a stronger than anticipated value of new business ("VONB") for the year ahead. A big factor in the improving share price for the business is the reopening of Hong Kong, given the popularity of visits there from mainland Chinese nationals.

Elsewhere, Japanese skincare leader, Shiseido saw its share price perform well this quarter. The business is a key beneficiary of the Chinese tourism, something that has been conspicuously absent as a result of the pandemic. Recent results were positive, with operating profit increasing by 111% on a year-on-year basis. Management has also announced that the CEO and President, Masahiko Uotani will transition to Chairman in the next two years, while the current CEO of Shiseido's Chinese business will be promoted to President and COO. Given the importance of China to our growth thesis we view this as a positive development.

Turning to detractors from performance, MercadoLibre, Coupang and Ritchie Brothers feature prominently.

MercadoLibre is the leading Latin American e-commerce platform. Results have continued to be strong (third quarter Gross Merchandise Value (GMV) +32%, Total Payment Volume +76% and a record Earnings Before Interest and Taxes (EBIT) margin of 11% driven by scale benefits coming through). The company continues to gain market share due to their e-commerce offering, competitive position and some significant missteps from the competition. Furthermore, the financial business continues to grow strongly.

Continuing the e-commerce theme, Coupang is a leading Korean e-commerce business which is seeing rapid growth and adoption of its services. It has a vertically integrated model and a highly driven founder and management team. Growth has continued to come through with revenues +27% year over year, well ahead of the competition. Active users have also ticked up, whilst Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) has tripled. We are encouraged by the focus on and move towards profitability Coupang has made over the past year.

Canadian industrial auctioneering business Ritchie Brothers has performed well in 2022, being a beneficiary of inflation. In the fourth quarter the business announced a potential acquisition of IAA (Insurance Auto Auctions), an auto salvage auctioneer. This was not received well by the market and caused the share price to de-rate. During the quarter we met with management to understand the merger better, in order to further understand what this transformational deal might mean. We continue to monitor the situation closely and its potential impact on the long-term prospects for the company.

Notable transactions

Throughout the quarter the Fund added three new names. AbCellera, an antibody discovery service for partners, improving research efficiency through its innovative technology. MIPS is a Swedish company behind the Brain Protection System for helmets. They integrate their technology into helmets, which can significantly reduce the impact of oblique collisions. EXOR is an Italian holding company, with a track record of effective capital deployment. It has a number of attractive underlying holdings, such as Ferrari, Stellantis, and CNH Industrial.

The Fund sold three names in the quarter, Ping an Healthcare and Technology, a Chinese telemedicine business, Hangzhou Tigermed, the largest Chinese Contract Research Organisation business and Temenos, a disruptive banking software business.

Transactions from 01 October 2022 to 31 December 2022.


New Purchases

Stock Name	Transaction Rationale
Abcellera Biologics	AbCellera provides antibody discovery services for pharmaceutical and biotech partners. AbCellera improves the speed, and potentially the quality, of antibody discovery by leveraging its in-house technology, which consists of a proprietary immunisation method, single cell screening, bi-specific antibody engineering, and supporting data and software. We believe that AbCellera's technology is differentiated and valuable, which will allow the company to capture an increasing share of antibody development programmes. We are also impressed by the calibre and thoughtfulness of AbCellera's management team and believe that it will continue to invest in technology and innovation to reinforce the company's competitive position. The antibody therapeutics market is large and growing and AbCellera monetises through high-margin milestone and royalty payments. We believe that there is the potential for a very attractive investment outcome, and have taken an initial holding.
EXOR	EXOR is the investment vehicle for the Agnelli family, whose fortunes were made in Fiat. It has an attractive range of underlying assets including Ferrari, Stellantis and CNH Industrial. Under the leadership of John Elkann the company is slowly repositioning itself, moving capital into new areas like luxury and healthcare at a time when it has a great deal of capital to deploy and valuations are depressed. Trading at a significant discount to NAV, EXOR's valuation fails to reflect the potential attractions for future value creation.
MIPS	MIPS is a Swedish company that has developed a Brain Protection System for helmets. This is a plastic insert that sits inside the helmet which absorbs some of the rotational force in the event of an oblique impact, reducing instances of brain damage and fatality. They work with helmet manufacturers to integrate the BPS into their product, and take a fee per helmet sold, making for a very attractive business model. There are opportunities to expand out from cycling into other types of helmets. Now is an attractive entry point into this potentially high quality business, and so we have taken a holding for your portfolio.

Complete Sales

Stock Name	Transaction Rationale
Hangzhou Tigermed Consulting	Hangzhou Tigermed is the largest contract research organization (CRO) in China, benefiting from the growth and outsourcing of domestic pharmaceutical research & development. Its competitive edge comes from its scale, which allows it to offer comprehensive and high-quality but relatively cheap services to its customers. Tigermed is agnostic as to which drug will be the next blockbuster, its chances of approval, or the pricing regime, making it a very resilient business model. While we continue to believe in the underlying growth case and in management's alignment and capital allocation skills, we have decided on a complete sale of this holding to fund new ideas, while remaining exposed to the tailwinds that support Tigermed's investment case.
Ping An Healthcare & Tech	Ping An Healthcare and Technology provides artificial intelligence assisted medical advice and online consultations with top-tier doctors. The investment case centred around China's lack of primary care and conflicting incentives with the hospital system. However, following new draft regulations, we now have greater concerns about the future of the business. Proposed changes include the requirement for doctors to be real-name verified and not an AI substitute, as well as stricter regulation on the ability to use a downloaded prescriptions from the app. These changes signal a misalignment with the state and we have therefore decided to sell your holding.
Temenos	We have sold your holding in financial services software provider Temenos. We continue to believe in the long-term growth opportunity that lies in updating the ageing software infrastructure upon which the global financial services industry is built. Unfortunately, while Temenos remains a leader in its field, the competitive pressure from younger and more disruptive market entrants continues to increase, and the shift in sales model it is going through from up-front licenses to subscription and "software as a service" could prove operationally and financially disruptive. Combined with diminished confidence in the executive team after a series of disappointing operational updates and turnover in the senior sales team, we no longer see the risk reward as attractively balanced, so we have decided to sell your holding.


Sector Analysis (%)



1	Industrials	24.30
2	Information Technology	19.17
3	Financials	16.97
4	Consumer Discretionary	15.12
5	Materials	6.56
6	Communication Services	6.36
7	Consumer Staples	5.51
8	Health Care	4.33
9	Cash	1.67

Total may not sum due to rounding. The composition of the Fund's holdings is subject to change. Percentages are based on securities at market value.

Geographic Analysis (%)



1	Europe (ex UK)	47.49
2	Emerging Markets	22.94
3	Developed Asia Pacific	19.43
4	UK	4.52
5	Canada	3.94
6	Cash	1.67

Total may not sum due to rounding. The composition of the Fund's holdings is subject to change. Percentages are based on securities at market value.

Top Ten Holdings

Holdings	Fund %	
1	AIA	3.77
2	MercadoLibre	3.30
3	TSMC	2.98
4	HDFC	2.67
5	Nestlé	2.40
6	Ryanair	2.24
7	SAP	2.24
8	Rio Tinto	2.20
9	Samsung Electronics	2.18
10	IMCD	2.18

The composition of the Fund's holdings is subject to change. Percentages are based on securities at market value.

Portfolio Characteristics

Number of holdings	74
Number of countries	25
Number of sectors	8
Number of industries	34
Active Share	86%*
Annual Turnover	18%

*Relative to MSCI ACWI ex US Index. Source: Baillie Gifford & Co, MSCI.

Voting Activity

Votes Cast in Favour		Votes Cast Against		Votes Abstained/Withheld	
Companies	10	Companies	1	Companies	None
Resolutions	70	Resolutions	2	Resolutions	None

In 2022 we continued to refine and improve our Environmental, Social and Governance (ESG) approach expanding available resource and further formalizing governance and oversight

The scope and scale of issues which fall under the ESG headline continues to increase. Remaining focused on relevance to the investment case remains the priority

We appreciate receiving your feedback on our ESG work. Please let us know if you have any comments or questions

Company Engagement

Engagement Type	Company
Corporate Governance	Danone S.A., Housing Development Finance Corporation Limited
Environmental/Social	AIA Group Limited, ASML Holding N.V., Chr. Hansen Holding A/S, MercadoLibre, Inc., Nexans S.A., Novozymes A/S, Rio Tinto Group, Ryanair Holdings plc, Samsung Electronics Co., Ltd., Shopify Inc., Taiwan Semiconductor Manufacturing Company Limited, Tencent Holdings Limited
AGM or EGM Proposals	Discovery Limited, Kering SA, Samsung Electronics Co., Ltd.
Executive Remuneration	Amadeus IT Group, S.A., Discovery Limited

There are four options that an engagement can be tagged as:

- 'Corporate Governance' (engagement on corporate governance issues and the governance of companies),
- 'Executive Remuneration' (pay of executives),
- 'Environmental/Social' (any issues)
- 'AGM or EGM Proposals' (engagement with proposals)

Votes Cast in Favour

Companies	Voting Rationale
Ambu, Chr Hansen Holding A/S, Cochlear, DSV, Discovery Ltd, HDFC Corp, Just Eat Takeaway.com, Rio Tinto, Samsung Electronics, Tencent Music Entertainment ADR	We voted in favour of routine proposals at the aforementioned meeting(s).

Votes Cast Against

Company	Meeting Details	Resolution(s)	Voting Rationale
Discovery Ltd	AGM 12/01/22	NB1.1	We opposed the remuneration policy due to concerns with the lack of long term performance measures.
Discovery Ltd	AGM 12/01/22	NB1.2	We opposed the implementation of the remuneration policy due to concerns with the lack of long term performance measures.

Votes Abstained

We did not abstain on any resolutions during the period.

Votes Withheld

We did not withhold on any resolutions during the period.

Asset Name	Fund %
AIA	3.77
MercadoLibre	3.30
TSMC	2.98
HDFC	2.67
Nestlé	2.40
Ryanair	2.24
SAP	2.24
Rio Tinto	2.20
Samsung Electronics	2.18
IMCD	2.18
Atlas Copco	2.15
Richemont	2.08
Deutsche Boerse	2.02
CRH	2.01
ASML	1.86
Edenred	1.80
Scout24	1.75
Sony	1.71
FinecoBank	1.67
Epiroc	1.61
Shiseido	1.59
DSV	1.58
Kingspan Group	1.55
Dassault Systemes	1.54
Danone	1.53
Experian	1.52
Tencent	1.50
FANUC	1.44
Rational	1.42
Kone	1.41
Hong Kong Exchanges & Clearing	1.41
DENSO	1.40
Amadeus IT Group	1.40
Meituan	1.33
Constellation Software	1.33
Novozymes	1.29
Discovery	1.27
Adyen	1.20
SMC	1.19
MonotaRO	1.17
Shimano	1.17
Tencent Music Entertainment Group	1.12
Sartorius Stedim Biotech	1.06
Keyence	1.05
Chr Hansen	1.05
Nintendo	1.05

Asset Name	Fund %
Japan Exchange Group	1.03
Copa Holdings	1.03
Kering	1.01
BioNTech	0.97
EXOR	0.95
Ping An Insurance	0.95
ICICI Lombard	0.92
Topicus.com	0.88
Alibaba	0.85
Prosus	0.84
Nidec Corporation	0.84
Coupang	0.83
Kuehne & Nagel	0.79
Shopify	0.71
Ritchie Bros. Auctioneers	0.63
Nexans	0.63
Cochlear	0.61
Aker Carbon Capture ASA	0.59
Spotify	0.53
Oxford Nanopore Tech	0.44
WuXi Biologics	0.44
MIPS	0.44
SEA Limited	0.41
Ambu	0.41
AbCellera Biologics	0.40
Wizz Air	0.35
Futu	0.32
Just Eat Takeaway.com	0.16
Norilsk Nickel	0.00
Magnit	0.00
Cash	1.67
Total	100.00

Total may not sum due to rounding. The composition of the Fund's holdings is subject to change. Percentages are based on securities at market value.

As at March 3rd 2022, two Russian holdings have been valued at zero by our Fair Value Pricing Committee due to the ongoing issues in the Russian market: Magnit, Norilsk Nickel

Important Information and Fund Risks

Past performance is not a guide to future returns. This document contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research and Baillie Gifford and its staff may have dealt in the investments concerned.

The Funds are distributed by Baillie Gifford Funds Services LLC. Baillie Gifford Funds Services LLC is registered as a broker-dealer with the SEC, a member of FINRA and is an affiliate of Baillie Gifford Overseas Limited.

All information is sourced from Baillie Gifford & Co unless otherwise stated. All amounts are in US dollars unless otherwise stated.

As with all mutual funds, the value of an investment in the Fund could decline, so you could lose money. The most significant risks of an investment in the Baillie Gifford International Alpha Fund are Investment Style Risk, Growth Stock Risk, Long-Term Investment Strategy Risk and Non-U.S. Investment Risk. The Fund is managed on a bottom up basis and stock selection is likely to be the main driver of investment returns. Returns are unlikely to track the movements of the benchmark. The prices of growth stocks can be based largely on expectations of future earnings and can decline significantly in reaction to negative news. The Fund is managed on a long-term outlook, meaning that the Fund managers look for investments that they think will make returns over a number of years, rather than over shorter time periods. Non-U.S. securities are subject to additional risks, including less liquidity, increased volatility, less transparency, withholding or other taxes and increased vulnerability to adverse changes in local and global economic conditions. There can be less regulation and possible fluctuation in value due to adverse political conditions. Other Fund risks include: Asia Risk, China Risk, Conflicts of Interest Risk, Currency Risk, Emerging Markets Risk, Equity Securities Risk, Environmental, Social and Governance Risk, Focused Investment Risk, Geographic Focus Risk, Government and Regulatory Risk, Information Technology Risk, Initial Public Offering Risk, Japan Risk, Large-Capitalization Securities Risk, Liquidity Risk, Market Disruption and Geopolitical Risk, Market Risk, Service Provider Risk, Settlement Risk, Small- and Medium-Capitalization Securities Risk and Valuation Risk.

For more information about these and other risks of an investment in the Fund, see "Principal Investment Risks" and "Additional Investment Strategies" in the prospectus. There can be no assurance that the Fund will achieve its investment objective.

Baillie Gifford International Alpha Fund seeks capital appreciation. There can be no assurance, however, that the Fund will achieve its investment objectives.

Any stock examples, or images, used in this presentation are not intended to represent recommendations to buy or sell, neither is it implied that they will prove profitable in the future. It is not known whether they will feature in any future portfolio produced by us. Any individual examples will represent only a small part of the overall portfolio and are inserted purely to help illustrate our investment style.

Legal Notices

Source: MSCI. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indexes or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

**Principal Office: Calton Square, 1 Greenside Row,
Edinburgh EH1 3AN, Scotland
Telephone: +44 (0)131 275 2000
bailliegifford.com**

**780 Third Avenue, 43rd Floor, New York, NY 10017
Telephone: (212) 319 4633**